{
  "abstract": "Background/Objectives To evaluate oral corticosteroid (OCS) usage at 1 year following efgartigimod (EFG) initiation.Methods Patients with generalised myasthenia gravis (gMG) using OCS pre-EFG initiation were identified from a US medical and pharmacy claims database (based on information licensed from IQVIA: Longitudinal Access and Adjudication Data [LAAD] for the period April 2016−December 2023, reflecting estimates of real-world activity [all rights reserved]). Mean (SD) average daily dose (ADD) of OCS was evaluated during the 3 months prior to, and at 6 and 12 months post-EFG initiation. To assess outcomes, de-identified Myasthenia Gravis Activities of Daily Living (MG-ADL) data collected in the ‘My VYVGART Path’ patient support program was tokenised and integrated into the primary dataset.Results 169 adults (≥18 years) who were using chronic OCS pre-EFG initiation, initiated EFG by December 31, 2022, and continued EFG for at least 12 months were included in the analysis. At 6 and 12 months post-EFG, respectively, 31 (18%) and 45 (27%) patients had no OCS usage. Overall mean (SD) OCS ADD was significantly reduced at 6 months (13.2 [13.9] mg/day, P<0.001), and at 12 months (10.2 [12.1] mg/day, P<0.001) post-EFG initiation compared with baseline (17.2 [13.7] mg/day). Among a subset of 72 patients (43%) who had both pre- and post-EFG MG-ADL scores available, best-follow up mean (SD) MG-ADL was significantly reduced (from 8.3 [3.7] to 3.4 [2.8], P<0.001).Conclusion The significant reduction of OCS usage observed at 6 months post-EFG initiation was retained at 12 months, while demonstrating MG-ADL response expected from EFG treatment.",
  "authors": [
    {
      "affiliations": [
        "Department of Neurology and Neurological Sciences, Stanford Medicine, Palo Alto, CA, USA"
      ],
      "name": "Neelam Goyal"
    },
    {
      "affiliations": [
        "Argenx Australia Pty. Ltd., Melbourne, VIC, Australia"
      ],
      "name": "Melissa Hardy"
    },
    {
      "affiliations": [
        "Argenx US Inc., Boston, MA, USA"
      ],
      "name": "Cynthia Qi"
    },
    {
      "affiliations": [
        "Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA"
      ],
      "name": "John Stone"
    },
    {
      "affiliations": [
        "Argenx US Inc., Boston, MA, USA"
      ],
      "name": "Edward Brauer"
    },
    {
      "affiliations": [
        "Argenx US Inc., Boston, MA, USA"
      ],
      "name": "Matthew Jefferson"
    },
    {
      "affiliations": [
        "ZS Associates, Bengaluru, Karnataka, India"
      ],
      "name": "Tharun Balaji Suthagar"
    },
    {
      "affiliations": [
        "ZS Associates, Bengaluru, Karnataka, India"
      ],
      "name": "Rohit R Menon"
    },
    {
      "affiliations": [
        "ZS Associates, New York, NY, USA"
      ],
      "name": "Mai Sato"
    },
    {
      "affiliations": [
        "Argenx BVBA, Ghent, Belgium"
      ],
      "name": "Glenn Phillips"
    }
  ],
  "title": "3463 Real-world reduction in oral corticosteroid utilization at 1 year following efgartigimod initiation",
  "uid": "5222fbb2-32a3-5528-a53c-2e223e9509b6"
}